MX348137B - Vacuna de la leishmaniasis con el uso del inmunogeno salival de la mosca de la arena. - Google Patents

Vacuna de la leishmaniasis con el uso del inmunogeno salival de la mosca de la arena.

Info

Publication number
MX348137B
MX348137B MX2014013606A MX2014013606A MX348137B MX 348137 B MX348137 B MX 348137B MX 2014013606 A MX2014013606 A MX 2014013606A MX 2014013606 A MX2014013606 A MX 2014013606A MX 348137 B MX348137 B MX 348137B
Authority
MX
Mexico
Prior art keywords
immunogen
sand fly
fly salivary
leishmania vaccine
leishmania
Prior art date
Application number
MX2014013606A
Other languages
English (en)
Inventor
Bernard Fischer Laurent
G Valenzuela Jesus
Original Assignee
Merial Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Ltd filed Critical Merial Ltd
Publication of MX348137B publication Critical patent/MX348137B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Insects & Arthropods (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a una composición que comprende un vector de expresión, en donde el vector comprende un polinucleótido que codifica uno o más polipéptidos que codifican uno o más polipéptidos LJM17 que tienen por lo menos 80% de identidad de secuencia con un polipéptido que tiene la secuencia según se establece en SEQ ID NO: 5, 7, 15 o 17 y en donde el vector de expresión se selecciona del grupo que consiste de pVR2001-TOPO, pVR2001-TOPA y ALVAC.
MX2014013606A 2008-05-08 2009-05-06 Vacuna de la leishmaniasis con el uso del inmunogeno salival de la mosca de la arena. MX348137B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5163508P 2008-05-08 2008-05-08
US10134508P 2008-09-30 2008-09-30
PCT/US2009/042980 WO2009137577A2 (en) 2008-05-08 2009-05-06 Leishmania vaccine using sand fly salivary immunogen

Publications (1)

Publication Number Publication Date
MX348137B true MX348137B (es) 2017-05-29

Family

ID=41110966

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2010012069A MX2010012069A (es) 2008-05-08 2009-05-06 Vacuna de la leishmaniasis con el uso del inmunogeno salival de la mosca de la arena.
MX2014013606A MX348137B (es) 2008-05-08 2009-05-06 Vacuna de la leishmaniasis con el uso del inmunogeno salival de la mosca de la arena.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2010012069A MX2010012069A (es) 2008-05-08 2009-05-06 Vacuna de la leishmaniasis con el uso del inmunogeno salival de la mosca de la arena.

Country Status (11)

Country Link
US (2) US8603808B2 (es)
EP (2) EP2283035B1 (es)
CN (2) CN103768588A (es)
AR (1) AR071696A1 (es)
BR (1) BRPI0915605B8 (es)
ES (1) ES2760004T3 (es)
HK (1) HK1150616A1 (es)
IL (1) IL209107A (es)
MA (1) MA32376B1 (es)
MX (2) MX2010012069A (es)
WO (1) WO2009137577A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010012069A (es) * 2008-05-08 2010-12-14 Merial Ltd Vacuna de la leishmaniasis con el uso del inmunogeno salival de la mosca de la arena.
MX2015002701A (es) 2012-08-30 2015-12-01 Merial Inc Dispositivo hiperbarico y metodos para producir vacunas inactivadas y para replegar/solubilizar proteinas recombinates.
US20160194660A1 (en) * 2012-12-21 2016-07-07 Merck Sharp & Dohme Corp. Expression vectors for recombinant protein production in mammalian cells
US10010499B2 (en) 2014-11-03 2018-07-03 Merial Inc. Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
AR111842A1 (es) 2017-06-02 2019-08-21 Amgen Inc Antagonistas de péptido pac1
CN113337542A (zh) * 2021-06-10 2021-09-03 山西大学 高效表达利什曼原虫pepck的人复制缺陷型重组腺病毒载体

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4963481A (en) 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system
AU613316B2 (en) 1986-09-12 1991-08-01 Genentech Inc. Improved recombinant expression
IL84154A0 (en) 1986-10-16 1988-03-31 Microgenesys Inc Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
DE3743138A1 (de) 1987-12-18 1989-09-14 Mayr Christian Gmbh & Co Kg Schleifringlose, elektromagnetische ueberlastkupplung
CA2003300A1 (en) 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
US6780407B1 (en) 1989-03-08 2004-08-24 Aventis Pasteur Pox virus comprising DNA sequences encoding CEA and B7 antigen
JP3602530B2 (ja) 1991-03-07 2004-12-15 ヴァイロジェネティクス コーポレイション 遺伝子操作したワクチン菌株
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
FR2712603B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
US5529780A (en) 1994-03-30 1996-06-25 Virogenetics Corporation Nucleotide and amino acid sequences of canine herpesvirus gB and gC
WO1996034109A1 (en) 1995-04-25 1996-10-31 Vical Incorporated Single-vial formulations of dna/lipid complexes
EP0803573A1 (en) 1996-04-25 1997-10-29 Gesellschaft für Biotechnologische Forschung mbH (GBF) Polycistronic expression construct with cytokines for multivalent vaccines
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
FR2750865B1 (fr) 1996-06-27 1998-12-04 Rhone Merieux Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2
AU737243B2 (en) 1996-07-03 2001-08-16 Merial, Inc. Recombinant canine adenovirus (CAV) containing exogenous DNA
US6090393A (en) 1996-07-03 2000-07-18 Merial Recombinant canine adenoviruses, method for making and uses thereof
US6156567A (en) 1996-07-03 2000-12-05 Merial Truncated transcriptionally active cytomegalovirus promoters
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
FR2776928B1 (fr) 1998-04-03 2000-06-23 Merial Sas Vaccins adn adjuves
TWI224107B (en) 1998-10-22 2004-11-21 Pfizer Prod Inc Novel proteins from actinobacillus pleuropneumoniae
US6017537A (en) 1998-12-18 2000-01-25 Connaught Laboratories, Inc. Formyl methionyl peptide vaccine adjuvant
US6645740B1 (en) 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
FR2796397B1 (fr) 1999-07-16 2006-09-01 Merial Sas Genes de calicivirus felin et vaccins notamment vaccins recombines
UA77152C2 (en) 1999-09-25 2006-11-15 Method for stimulation of immune response using nucleic acid-containing immunostimulating compositions, method for treatment of cancer and method for treatment or prophylaxis of allergy or asthma
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
EP1203819A3 (en) 2000-10-06 2002-08-07 Transgene S.A. Anti-inflammatory vectors
EP1407039A4 (en) * 2001-06-19 2005-12-21 Us Gov Health & Human Serv ANTI-ARTHROPOD VECTOR VACCINES AND SELECTION TECHNIQUES AND USES THEREOF
FR2829498B1 (fr) 2001-09-11 2003-11-28 Merial Sas Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins
WO2003062374A2 (en) 2001-11-09 2003-07-31 Entremed, Inc. Synthetic genes for malarial proteins and methods of use
WO2004024027A2 (en) 2002-06-07 2004-03-25 University Of Florida Endodontic files made using bulk metallic glasses
ES2447843T3 (es) * 2002-10-29 2014-03-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polip�ptidos de Lutzomyia longipalpis y m�todos de uso
BRPI0412913B1 (pt) * 2003-10-24 2018-04-03 Mologen Ag Métodos para usar uma construção da expressão de dna; usar duas ou três construções da expressão de dna; usar as construções da expressão de dna para a produção de uma vacina para o tratamento de doenças de infecções por leishmaniose; usar duas ou três construções da expressão de dna para a produção de uma vacina para o tratamento de doenças de infecções por leishmaniose; construções da expressão de dna; e vacina para o tratamento de doenças de infecções por leishmaniose
RS52705B (en) 2004-06-04 2013-08-30 Merial Limited Administration of FeLV Vaccine Without Needle
US7512883B2 (en) * 2004-06-30 2009-03-31 Microsoft Corporation Portable solution for automatic camera management
CA2540736A1 (en) * 2005-04-08 2006-10-08 Institut Pasteur Polypeptides of leishmania major and polynucleotides encoding same and vaccinal, therapeutical and diagnostic applications thereof
US7794736B2 (en) * 2006-11-21 2010-09-14 Merial Limited Canine Leishmania vaccine
US20100278752A1 (en) * 2007-08-02 2010-11-04 Rhode Island Board Of Governors For Higher Education Methods for Detection and Prevention of Tick Infestation and Pathogen Transmission
MX2010012069A (es) * 2008-05-08 2010-12-14 Merial Ltd Vacuna de la leishmaniasis con el uso del inmunogeno salival de la mosca de la arena.
US8410258B2 (en) * 2008-05-21 2013-04-02 Infections Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
EP2300051B1 (en) * 2008-05-21 2014-11-12 Infectious Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
WO2010078466A2 (en) * 2008-12-31 2010-07-08 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Sand fly salivary proteins with anti-complement activity and methods of their use
WO2010078469A2 (en) * 2008-12-31 2010-07-08 The Usa As Represented By The Secretary, Department Of Health And Human Services Sand fly salivary proteins as novel factor xa inhibitors and methods of use
JP5981436B2 (ja) * 2010-10-01 2016-08-31 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 寄生的に感染している対象におけるワクチン不応答性を反転させるためのリステリアワクチンベクターの使用
BR112013012482A8 (pt) * 2010-11-18 2017-07-11 Merial Ltd Modelo de desafio para leishmaniose canina por picadas de mosquito-palha
WO2013011184A2 (es) * 2011-07-21 2013-01-24 Consejo Superior De Investigaciones Científicas (Csic) Molécula quimerica util en inmunoterapia frente a la leishmaniosis, que comprende un fragmento de la proteina pfr1 de leishmania infantum con epitopes especificos inmunodominantes
WO2013142371A1 (en) * 2012-03-20 2013-09-26 Merial Limited Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein c and uses thereof

Also Published As

Publication number Publication date
US20090324649A1 (en) 2009-12-31
ES2760004T3 (es) 2020-05-12
MX2010012069A (es) 2010-12-14
WO2009137577A3 (en) 2010-03-25
IL209107A (en) 2017-08-31
BRPI0915605B8 (pt) 2021-09-08
EP2899203A2 (en) 2015-07-29
US20140294875A1 (en) 2014-10-02
EP2899203A3 (en) 2015-08-05
MA32376B1 (fr) 2011-06-01
EP2283035A2 (en) 2011-02-16
EP2283035B1 (en) 2015-07-29
AR071696A1 (es) 2010-07-07
BRPI0915605A2 (pt) 2016-02-02
EP2899203B1 (en) 2019-07-10
BRPI0915605B1 (pt) 2021-08-24
WO2009137577A2 (en) 2009-11-12
CN102066411A (zh) 2011-05-18
IL209107A0 (en) 2011-01-31
US8603808B2 (en) 2013-12-10
CN103768588A (zh) 2014-05-07
HK1150616A1 (zh) 2012-01-06
US9228002B2 (en) 2016-01-05

Similar Documents

Publication Publication Date Title
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
MX360415B (es) Vectores poxvirales recombinantes que expresan proteinas tanto de rabia como de ox40, y vacunas hechas a partir de los mismos.
EA201070329A1 (ru) Векторы и конструкции для доставки гриппозного антигена
PH12014501835A1 (en) Novel adjuvant compositions
PH12015500092A1 (en) Compositions for immunising against staphylococcus aureus
MX348137B (es) Vacuna de la leishmaniasis con el uso del inmunogeno salival de la mosca de la arena.
MY154956A (en) Chimeric adenoviral vectors
WO2008060669A3 (en) Vaccine for avian influenza and methods of use
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
PH12014501795B1 (en) Rotavirus subunit vaccines and methods of making and use thereof
MX2013012219A (es) Método de administración de vacunas.
WO2009114085A3 (en) Allogeneic cancer cell-based immunotherapy
EP2376654A4 (en) VACCINES TARGETING CELL DEATH RECEPTORS
TN2009000195A1 (en) Prime boost canine leishmania vaccine
NZ700470A (en) Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein c and uses thereof
GEP201706766B (en) Methods and compositions for vaccinating against staphylococcus aureus
MX2011004219A (es) Vacuna contra el virus de la peste equina africana.
CL2011002994A1 (es) Construccion de proteina que comprende polipeptido casb7439; composicion inmunogenica que comprende dicha construccion; uso de la composicion porque sirve para inducir respuesta inmunitaria al casb7439 en un animal.
CY1125328T1 (el) Ανασυνδυασμενο εμβολιο ιου λευχαιμιας αιλουροειδων περιεχοντας βελτιστοποιημενο γονιδιο φακελου ιου λευχαιμιας αιλουροειδων
UA101385C2 (ru) Иммунологическая композиция, которая в качестве адъюванты содержит сульфолипо-циклодекстрин (sl-cd) и сапонин
TN2010000500A1 (en) Leishmania vaccine using sand fly salivary immunogen
MX361804B (es) Vacunas genéticas contra el virus hendra y el virus nipah.
GB0703976D0 (en) Liposome preparation
MX2010008170A (es) Vacunas para influenza canina.
UA104138C2 (en) Novel adjuvant compositions